10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

Impact · against what's priced in

The purchase of 10,726 shares of LXEO by Ethic Inc. is a negligible event. With a total position value of only $44,000, this trade is too small to shift institutional sentiment or impact the stock price.

LXEO+0.01: No priced-in read yet
In context: Ethic Inc. established a tiny position of 10,726 shares valued at $44,000, which is too small to be a meaningful catalyst for the stock.
Read from the article alone

10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

biotech▲51%
pharmaceuticals▲18%
13f
LXEO
institutional ownership
sec filing

Top 2 movers · tap to explore

10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

What matters in this story

How each ticker is affected

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

What matters in this story

How each ticker is affected

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Track these names every morning.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

What matters in this story

How each ticker is affected

Next reads from the same story arc

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

What matters in this story

How each ticker is affected

Next reads from the same story arc

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Track these names every morning.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026